<DOC>
	<DOCNO>NCT02386800</DOCNO>
	<brief_summary>This roll-over protocol allow patient still receive clinical benefit continue treat multiple protocols one program span multiple indication completion parent study/ ( y ) . The population roll-over study consistent population define program parent study/ ( y ) . The primary eligibility criterion patient enter roll-over protocol participation completion Novartis OGD &amp; GMA/Incyte study ruxolitinib . Efficacy parameter would measure ; however safety data collect . Patients complete prior study ruxolitinib assess Investigator continue benefit ongoing treatment investigational ruxolitinib eligible .</brief_summary>
	<brief_title>CINC424A2X01B Rollover Protocol</brief_title>
	<detailed_description />
	<mesh_term>Splenomegaly</mesh_term>
	<criteria>1 . Patient currently enrol Novartis OGD GMAsponsored Incytesponsored clinical study ( Incyte delegate sponsorship preferred CRO , applicable ) approve enroll rollover study , receive ruxolitinib fulfil requirement parent protocol . 2 . Patient currently benefit treatment ruxolitinib , determine investigator 3 . Patient demonstrate compliance , assess investigator , parent study protocol requirement Willingness ability comply schedule visit , treatment plan study procedures 4 . Patient currently evidence progressive disease , determine investigator , follow previous treatment ruxolitinib 5 . Written inform consent obtain prior enrol rollover study receive study medication . If consent express writing , must formally document witnessed , ideally via independent trusted witness . 1 . Patient permanently discontinue study treatment parent study due reason . Patient 's indication currently approve reimbursed local country 2 . Patient participate combination trial ruxolitinib dispense combination another study medication patient still receive combination therapy . 3 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . 4 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception throughout study duration inclusive 30day safety follow .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic idiopathic myelofibrosis ,</keyword>
	<keyword>post polycythemia vera myelofibrosis ,</keyword>
	<keyword>post essential thrombocythaemia myelofibrosis .</keyword>
</DOC>